Today on Drug Discovery & Development
FDA approves second indication of AbbVie’s Skyrizi for adults with active psoriatic arthritis
FDA first approved AbbVie’s (NYSE:ABBV) interleukin-23 inhibitor Skyrizi (risankizumab-rzaa) for moderate to severe plaque psoriasis in 2019. Now, the agency has extended the approval to include adults with active psoriatic arthritis (PsA), which affects almost one out of three people with psoriasis. To win the new indication, AbbVie provided data from the KEEPsAKE-1 and KEEPsAKE-2 pivotal studies.…
Patient groups voice disapproval for CMS proposal to limit coverage of aducanumab
Biogen’s (NSDQ:BIIB) Alzheimer’s drug Aduhelm (aducanumab) continues to be a source of contention. Advocates cite the need for a new therapy for the memory-robbing disease while skeptics remain unconvinced about the benefit-risk profile of the drug. Most recently, Alzheimer’s disease advocates have criticized Medicare’s proposal to constrain coverage for the drug to clinical trial participants. The…
Drug Discovery and Development See More >
BD boasts of a landmark advancement in flow cytometry
BD (NYSE:BDX) touted a study on innovation in flow cytometry that featured as the cover story of the journal Science. Franklin Lakes, New Jersey-based BD’s study was conducted in collaboration with the European Molecular Biology Laboratory (EMBL). It evaluated BD’s flow cytometry efforts that add fluorescence imaging and image-based decision-making to sort individual cells at high…
Sponsored Content See More >
These are not fireworks: The objective truthBy Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…
AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…
What is Human AB Serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
DNA Script raises $165M Series C for DNA printing platform
DNA Script announced today that it raised $165 million in a Series C financing round, bringing its total capital raised to $280 million. South San Francisco-based DNA Script earmarked the funds raised to accelerate expansion and commercialization for the company’s Syntax benchtop nucleic acid printer and to broaden its portfolio of products powered by enzymatic…
Infectious Disease See More >
FDA extends approval of remdesivir to encompass non-hospitalized high-risk
Gilead Sciences’ (NSDQ:GILD) Veklury (remdesivir) became the first FDA-approved COVID-19 drug when it was approved in October 2020. Now, the company has announced that the FDA has granted expedited approval of a supplemental new drug application (sNDA) for the drug to treat non-hospitalized adult and adolescent patients with a high risk of progression to severe…
Valneva shares surge 30% after announcing its vaccine candidate neutralized omicron in neutralizing antibody study
Leyden Labs licenses monoclonal antibody for influenza A and B from Janssen
How Vir Biotechnology intends to functionally cure HIV and prevent malaria
GSK and Vir file for EUA for intramuscular administration of sotrovimab to treat COVID-19
Oncology See More >
Zymeworks to cut headcount at least 25% by end of 2022
Soon after taking the reins of Zymeworks (NYSE:ZYME), new Chair and CEO Kenneth Galbraith has decided to sharpen the company’s focus and reduce the firm’s headcount. To free up cash, the company plans to lay off at least one-quarter of its staff, including 10 members (50%) of its senior management team. The Vancouver–headquartered company also intends to…
Brazilian regulators authorize Sorrento Phase 2 clinical trial of COVI-MSC in COVID-19 long-haulers
FDA grants Enhertu priority review for HER2-positive positive metastatic breast cancer
NeuroMetrix’s Quell wins FDA breakthrough designation to treat certain chemo side effects
